Page last updated: 2024-12-06

trioxifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trioxifene is a nonsteroidal selective estrogen receptor modulator (SERM) that has shown potential as a treatment for various conditions. It is structurally similar to tamoxifen, another SERM, but with modifications to its chemical structure. Trioxifene has been studied for its effects on breast cancer, osteoporosis, and other estrogen-dependent conditions. It exhibits anti-proliferative effects in breast cancer cells and has demonstrated bone-protective properties in animal models. Research into trioxifene's therapeutic potential is ongoing, focusing on its effectiveness, safety profile, and potential to address unmet medical needs. '

trioxifene: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50139
CHEMBL ID110057
SCHEMBL ID4651963
MeSH IDM0063861

Synonyms (21)

Synonym
trioxifene
CHEMBL110057
[2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
63619-84-1
trioxifeno
methanone, (3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-
trioxifenum [inn-latin]
(3,4-dihydro-2-(4-methoxyphenyl)-1-naphthyl)(4-(2-(1-pyrrolidinyl)ethyl)phenyl)keton
trioxifenum
r0130f043h ,
lilly 88571
unii-r0130f043h
trioxifeno [inn-spanish]
3,4-dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl)ketone
trioxifene [inn]
3,4-dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl ketone
IHGLINDYFMDHJG-UHFFFAOYSA-N
[2-(4-methoxyphenyl)-3,4-dihydronaphth-1-yl][4-(1-pyrrolidinyl-2-ethoxy)phenyl] methanone
SCHEMBL4651963
DTXSID30212997
Q7843173

Research Excerpts

Overview

Trioxifene (LY133314) is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor alpha.

ExcerptReferenceRelevance
"Trioxifene (LY133314) is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor alpha (ERalpha) and antagonistic activity against ERalpha-mediated gene expression. "( The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Chedid, M; Chen, K; Goode, RL; Graff, JR; Johnson, MA; Jones, CD; Krishnan, V; Lynch, R; McNulty, AM; Neubauer, BL; Osborne, HE, 2003
)
2.03

Dosage Studied

ExcerptRelevanceReference
" Oral administration of the estrogen antagonist MER-25 at two dosage levels (15 and 30 mg/kg/day) to the pregnant baboon from days 35 to 55 after conception results in a decline in peripheral plasma levels of progesterone within a few days and persists for at least 20 days after the termination of treatment with no effect on plasma estradiol levels."( The effect of estrogen antagonism on progesterone production in early pregnancy in the baboon (Papio cynocephalus).
Castracane, VD; Goldzieher, JW; Kuehl, TJ, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID69531Relative binding affinity against estrogen receptor(ER)1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.
AID185420Percent inhibition of estradiol stimulated uterine growth in rats1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.
AID38726Relative binding affinity against Antiestrogen binding site(AEBS)1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.
AID187060Estrogenic activity as mean uterine weight in rats on 10 ug dose1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.
AID187059Antiestrogenic activity in presence of unlabeled estradiol as mean uterine weight in rats at 0.3 ug dose1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (66.67)18.7374
1990's5 (27.78)18.2507
2000's1 (5.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.95 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (10.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]